ChemicalBook
Chinese english Germany Korea

トラメチニブ

トラメチニブ 化学構造式
871700-17-3
CAS番号.
871700-17-3
化学名:
トラメチニブ
别名:
N-[3-[3-シクロプロピル-5-[(2-フルオロ-4-ヨードフェニル)アミノ]-3,4,6,7-テトラヒドロ-6,8-ジメチル-2,4,7-トリオキソピリド[4,3-d]ピリミジン-1(2H)-イル]フェニル]アセトアミド;トラメチニブ
英語化学名:
Trametinib
英語别名:
CS-30;100836;TraMetinib;CB32514557;GSK-1120212;TraMetinib API;QuMei iMatinib;Trametinib, >=98%;Trametinib Impurity;Mekinist trametinib
CBNumber:
CB32514557
化学式:
C26H23FIN5O4
分子量:
615.39
MOL File:
871700-17-3.mol

トラメチニブ 物理性質

融点 :
300-301 °C
比重(密度) :
1.74
外見 :
White solid.
酸解離定数(Pka):
14.76±0.70(Predicted)

安全性情報

Sフレーズ  24/25
HSコード  29339900

トラメチニブ 価格

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入

トラメチニブ 化学特性,用途語,生産方法

効能

抗悪性腫瘍薬, マイトジェン活性化細胞外シグナル関連キナーゼ(MEK)阻害薬

使用

Used in the systematic treatment of advanced cutaneous melanoma. An EGFR kinase inhibitor.

使用

antiprotozoal

定義

ChEBI: A pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment.

適応症

MEK, also known as MAPK, is a dual specificity threonine/tyrosine kinase that is a key node in the Raf–Ras–MEK signaling pathway. Small-molecule MEK inhibitors represent the largest group of type III allosteric inhibitors that do not bind to the ATP binding pocket. As of December 2016, besides the FDA-approved MEK1/2 inhibitors trametinib (Mekinist(R), GlaxoSmithKline) and cobimetinib (Cotellic(R), Roche), over 10 MEK inhibitors are currently in clinical trials. Trametinib was approved by FDA in 2013 for the treatment of patients with either B-Raf V600E or V600K mutated metastatic melanoma. Considering the fact that MEK and Raf are different kinases along the same pathway of Ras–Raf–MEK/ERK signaling cascade, combination strategies using both MEK and B-Raf inhibitors were utilized to overcome the observed progression using single-agent trametinib, which usually occurs within 7months. FDA approved the combination of trametinib and dabrafenib for the treatment of B-Raf V600E/K mutated metastatic melanoma in January 2014 and the combination of cobimetinib and vemurafenib for the same type of indication. Although significant improvement in progression-free survival was observed using MEK/B-Raf combination strategy, the incidence of some common adverse effects, such as vomiting, diarrhea, nausea, rash, and pyrexia, also increased.

臨床応用

Trametinib (GSK1120212) is an oral MEK inhibitor which has demonstrated excellent results in combination therapy for BRAF-mutated melanoma and is FDA approved in combination with BRAF inhibitors for that indication. Trametinib was evaluated initially as a single agent in KRAS mutant NSCLC in comparison with docetaxel and pemetrexed. Results as a single agent were not impressive, with an ORR of only 12% in these patients.

トラメチニブ 上流と下流の製品情報

原材料

準備製品


トラメチニブ 生産企業

Global( 237)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Jurong Coupling Biotechnology Co., Ltd.
13656108824
coupling278191416@hotmail.com CHINA 184 58
BIONNA MEDICINE CO.,LTD
18518759099
790226113@qq.com CHINA 52 58
Henan DaKen Chemical CO.,LTD.
+86-371-66670886
info@dakenchem.com China 20907 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22607 55
Hangzhou FandaChem Co.,Ltd.
008615858145714
+86-571-56059825 fandachem@gmail.com CHINA 8909 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3013 60
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 sales@fine-chemtech.com CHINA 890 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 26762 60
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 29954 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 968 58

871700-17-3(トラメチニブ)キーワード:


  • 871700-17-3
  • N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide GSK-1120212
  • Trametinib free base
  • Mekinist trametinib
  • Trametinib (GSK1120212,JTP 74057)
  • Trametinib, >=98%
  • CS-30
  • Trametinib Impurity
  • 100836
  • Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-
  • N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-tri
  • GSK-1120212
  • N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide
  • TraMetinib
  • GSK-1120212(traMetinib,JTP-74057)
  • JTP-74057, GSK212, TRAMETINIB
  • GSK1120212 (JTP-74057)
  • TraMetinib/GSK1120212
  • GSK1120212 ,TraMetinib
  • TraMetinib API
  • N-(3-{3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)aMino]-6,8-diMethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyriMidin-1(2H)-yl}phenyl)acetaMide
  • CB32514557
  • GSK1120212 (JTP-74057, TraMetinib)
  • N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)aMino]
  • GSK-1120212 N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide
  • Trametinib, 98%, a MEK1/2 inhibitor
  • QuMei iMatinib
  • N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
  • Trametinib (GSK1120212,JTP 74058)
  • Trametinib USP/EP/BP
  • Trametinib Trametinib
  • N-[3-[3-シクロプロピル-5-[(2-フルオロ-4-ヨードフェニル)アミノ]-3,4,6,7-テトラヒドロ-6,8-ジメチル-2,4,7-トリオキソピリド[4,3-d]ピリミジン-1(2H)-イル]フェニル]アセトアミド
  • トラメチニブ
Copyright 2017 © ChemicalBook. All rights reserved